Publication: Nature Nanotechnology
Filip Bošković, Jinbo Zhu, Ran Tivony, Alexander Ohmann, Kaikai Chen, Mohammed F. Alawami, Milan Đorđević, Niklas Ermann, Joana Pereira Dias, Michael Fairhead, Mark Howarth, Stephen Baker, Ulrich F. Keyser
16 January 2023
Respiratory infections are the major cause of death from infectious disease worldwide. Multiplexed diagnostic approaches are essential as many respiratory viruses have indistinguishable symptoms.
We created self-assembled DNA nanobait that can simultaneously identify multiple short RNA targets. The nanobait approach relies on specific target selection via toehold-mediated strand displacement and rapid read-out via nanopore sensing. Here, we show this platform can concurrently identify several common respiratory viruses, detecting a panel of short targets of viral nucleic acids from multiple viruses.
Our nanobait can be easily reprogrammed to discriminate viral variants, as we demonstrated for several key SARS-CoV-2 variants with single-nucleotide resolution. Lastly, we show that nanobait discriminates
between samples extracted from oropharyngeal swabs from negative and positive SARS-CoV-2 patients
Our system allows for multiplexed identification of native RNA molecules, providing a new scalable approach for diagnostics of multiple respiratory viruses in a single assay.View publication
2Association of Collagen, Elastin, Glycosaminoglycans, and Macrophages With Tissue Ultimate Material Strength and Stretch in Human Thoracic Aortic Aneurysms: A Uniaxial Tension Study
Publication: J Biomech Eng.
Aziz Tokgoz, Shuo Wang, Priya Sastry, Chang Sun, Nichola L. Figg, Yuan Huang, Martin R. Bennett, Sanjay Sinha, Jonathan H. Gillard, Michael P. F. Sutcliffe, Zhongzhao Teng
25 April 2022
Fiber structures and pathological features, e.g., inflammation and glycosaminoglycan (GAG) deposition, are the primary determinants of aortic mechanical properties which are associated with the development of an aneurysm. This study is designed to quantify the association of tissue ultimate strength and extensibility with the structural percentage of different components, in particular, GAG, and local fiber orientation.View publication
Publication: BMJ Open
Christian Philip Stickels, Ramesh Nadarajah, Chris P Gale, Houyuan Jiang, Kieran J Sharkey, Ben Gibbison, Nick Holliman, Sara Lombardo, Lars Schewe, Matteo Sommacal, Louise Sun, Jonathan Weir-McCall, Katherine Cheema, James H F Rudd, Mamas Mamas, Feryal Erhun
17 June 2022
An international team of researchers has modelled the impact that increasing treatment capacity and using a quicker, less invasive treatment option would have on waiting lists. Even in the best-case scenario, they found that the waiting list would take nearly a year to clear.
The traditional treatment for aortic stenosis involves replacing the narrowed valve, most commonly through open heart surgery (a surgical aortic valve replacement, SAVR). However, a newer keyhole procedure called a transcatheter aortic valve implantation (TAVI) is increasingly being used and is now recommended for patients aged 75 and over.
The researchers investigated the impact that increasing treatment capacity and converting a proportion of operations to the quicker TAVI procedure would have on the backlog. They looked at how long it would take to clear the backlog and found that the best and most achievable option involved a combination of increasing capacity by 20 per cent and converting 40 per cent of procedures from SAVR to TAVI. This would clear the backlog within 343 days with 784 deaths while people wait for treatment. Read the full story.View publication
4Diagnosis of patients with heart failure with preserved ejection fraction in primary care: cohort study
Publication: ESC Heart Failure
Faye Forsyth, James Brimicombe, Joseph Cheriyan, Duncan Edwards, F. D. Richard Hobbs, Navazh Jalaludeen, Jonathan Mant, Mark Pilling, Rebekah Schiff, Clare J. Taylor,M. Justin Zaman, Christi Deaton
21 September 2021
This paper illustrates the challenges of finding patients with heart failure with preserved ejection fraction (HFpEF) in primary care, and that many patients with likely HFpEF will not have their diagnosis confirmed. Greater awareness of HFpEF in primary care and improved diagnostic pathways are needed.View publication
5Characteristics of patients with heart failure with preserved ejection fraction in primary care: a cross-sectional analysis
Publication: BJGP Open
, , , , , , , , , , ,
14 December 2021
Compared with patients with other heart failure diagnoses in primary care, those with heart failure with preserved ejection fraction (HFpEF) are more likely to be women, obese, prefrail/frail, more functionally impaired and report more symptoms.View publication
6Clinical and demographic correlates of accelerometer-measured physical activity in participants enrolled in the OPTIMISE HFpEF study
Publication: European Journal of Cardiovascular Nursing
9 April 2021
This is a baseline analysis of physical activity (measured by accelerometer) of 124 patients, comparing those with confirmed heart failure with preserved ejection fraction (HFpEF) and those without HFpEF but with other HF diagnoses.View publication
Publication: Nature Metabolism
Scott C. Ritchie, Samuel A. Lambert, Matthew Arnold, Shu Mei Teo, Sol Lim, Petar Scepanovic, Jonathan Marten, Sohail Zahid, Mark Chaffin, Yingying Liu, Gad Abraham, Willem H. Ouwehand, David J. Roberts, Nicholas A. Watkins, Brian G. Drew, Anna C. Calkin, Emanuele Di Angelantonio, Nicole Soranzo, Stephen Burgess, Michael Chapman, Sekar Kathiresan, Amit V. Khera, John Danesh, Adam S. Butterworth & Michael Inouye
8 November 2021
For the first time, scientists have used polygenic scoring to identify molecular drivers of cardiovascular disease and diabetes, which could be targeted to help prevent or treat some of these conditions.View publication
Publication: NEJM Evidence
Tian X. Zhao, Rouchelle S. Sriranjan, Zewen Kelvin Tuong, Yuning Lu, Andrew P. Sage, Meritxell Nus, Annette Hubsch, Fotini Kaloyirou, Evangelia Vamvaka, Joanna Helmy, Michalis Kostapanos, Navazh Jalaludeen, David Klatzmann, Alain Tedgui, James H.F. Rudd, Sarah J. Horton, Brian J.P. Huntly, Stephen P. Hoole, Simon P. Bond, Menna R. Clatworthy, Joseph Cheriyan, and Ziad Mallat,
22 November 2021
Atherosclerosis is a chronic inflammatory disease of the artery wall. Regulatory T cells (Tregs) limit inflammation and promote tissue healing. Low doses of interleukin (IL)-2 have the potential to increase Tregs, but its use is contraindicated for patients with ischemic heart disease.
In a randomized, double-blind, placebo-controlled, dose-escalation trial, researchers tested low-dose subcutaneous aldesleukin (recombinant IL-2), given once daily for 5 consecutive days.View publication
9SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe
Publication: European Heart Journal
SCORE2 working group and ESC Cardiovascular risk collaboration
13 June 2021
The researchers analysed data from nearly 700,000 mainly middle-aged participants in 45 large-scale studies to develop risk prediction models (SCORE2) tailored for use in European countries.
The participants did not have previous history of CVD at the outset and 30,000 had a CVD event (heart attack or stroke) during the first 10 years of follow up.
These risk models were then statistically adapted or ‘recalibrated’ to more accurately estimate CVD risk for contemporary populations in four European risk regions, using data on population-specific CVD incidence rates and risk factor values from 10.8 million individuals. Read the full storyView publication
10Human embryonic stem cell-derived cardiomyocytes express SARS-CoV-2 host entry proteins: screen to identify inhibitors of infection
Publication: bioRxiv Preprint
Thomas L. Williams, Maria T. Colzani, Robyn G.C. Macrae, Emma L. Robinson, Stuart Bloor, Edward J. D. Greenwood, Jun Ru Zhan, Gregory Strachan, Rhoda E. Kuc, VDuuamene Nyimanu, View Janet J. Maguire, Paul J. Lehner, Sanjay Sinha, Anthony P. Davenport
21 January 2021
Patients with heart disease are more susceptible to severe infection with SARS CoV-2, and the virus is thought to damage cardiovascular tissue. Researchers developed a test to screen medicines that are currently in use for other conditions to see if they would block the entry of the SARS-CoV-2 virus and protect the heart and surrounding tissues.
Researchers found beating heart cells have the same special proteins SARS-CoV-2 virus uses to enter the patient’s tissues and used these cells to model a new system. Safely done in the laboratory, researchers looked at a virus and concentrated on the spike protein so it can infect the cells, but once inside the virus was unable to make copies of itself.
The researchers were then able to test compounds and licenced medicines to block the virus entering the heart cells in order to find a suitable treatment. This new screening gives the opportunity to test a wide range of medicines as well as new anti-viral drugs that are currently being developed.
Doing this and blocking entry of the virus can protect the heart and other tissues during infection. It will also help finding the best medicine to help stop patients getting seriously ill from SARS CoV-2.View publication
11Adverse clinical outcomes associated with RAAS inhibitor discontinuation: analysis of over 400 000 patients from the UK Clinical Practice Research Datalink (CPRD)
Publication: Clinical Kidney Journal
Toby J L Humphrey, Glen James, Eric T Wittbrodt, Donna Zarzuela, Thomas F Hiemstra
30 January 2021
In an observational study analysing data from over 430,000 patients, those who had their RAASi – blood pressure medications – interrupted or stopped, were found to have worse outcomes than those who continued with their treatment.
The patients who had medication interruptions or discontinuated were more likely to be hospitalised, to have a cardiac arrest or develop kidney damage than those who continued on their RAASi medications throughout the study.
This study highlights that the potential risks for and against RAASi treatment interruption or discontinuation be very carefully considered in patients for whom guideline-recommended RAAS inhibitor therapy is indicated.View publication
Eric L. Harshfield, Lisa Pennells, Joseph, Schwartz, Peter Willeit, Stephen Kaptoge, Steven Bell, Jonathan A. Shaffer, Thomas Bolton, Sarah Spackman, Sylvia Wassertheil-Smoller, Frank Kee, Philippe Amouyel, Steven J. Shea, Lewis H. Kuller, Jussi Kauhanen, E. M. van Zutphen, Dan G. Blazer, Harlan Krumholz, Paul J. Nietert, Daan Kromhout, MD19; Gail Laughlin, Lisa Berkman, Robert B. Wallace, Leon A. Simons, Elaine M. Dennison, Elizabeth L. M. Barr, Haakon E. Meyer, Angela M. Wood, John Danesh, Emanuele Di Angelantonio, Karina W. Davidson
15 December 2020
People who experience symptoms of depression are more likely to go on to develop heart disease or suffer a stroke than those who report good mental health.
Researchers analysed the health records of over half a million people, with no prior history of heart and circulatory disease, who were enrolled to two different studies.
Upon joining the studies, participants were given a score based on questionnaires assessing their mood and any symptoms of depression that they had experienced over the previous one to two weeks.
Over 10, researchers have found that those in the highest scoring group, and with most severe symptoms of depression, were more likely to have since developed heart disease or to have had a stroke, compared to people with the lowest scores.View publication
13Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals
Publication: Nature Genetics
Praveen Surendran, Joanna M. M. Howson et al
23 November 2020
Increased blood pressure (BP) is a major risk factor for cardiovascular disease (CVD) and related disability worldwide. Identifying biological pathways associated with blood pressure is important to understand the aetiology of CVD.
In this study involving collaborators from across the globe, and participants from diverse ancestries, researchers investigated whether genetic variants that a small proportion of people carry have an impact on blood pressure regulation and more readily implicate the genes underlying blood pressure regulation.
They identified 87 such genetic variants influencing blood pressure regulation that only a small proportion of people carry. In addition to identifying novel candidate genes associated with blood pressure, they showed a potential link between foetal development and an inverse relationship between systolic and diastolic blood pressure with stroke.
As shown in this study, a complex outcome like blood pressure requires large sample sizes to detect genetic variation associated with blood pressure that are rare in humans; studies to date have mainly looked at genetic variants that are carried by many people and therefore have very small effects on blood pressure regulation.
This study contributes to a significant improvement in researchers’ understanding of key genes controlling a risk factor like BP so they can better understand complex diseases like CVD and help identify new blood pressure therapies.View publication
Publication: European Respiratory Journal
Anthony W. Martinelli, Tejas Ingle, Joseph Newman, Iftikhar Nadeem, Karl Jackson, Nicholas D. Lane, James Melhorn, Helen E. Davies, Anthony J. Rostron, Aldrin Adeni, Kevin Conroy, Nicholas Woznitza, Matthew Matson, Simon E. Brill, James Murray, Amar Shah, Revati Naran, Samanjit S. Hare, Oliver Collas, Sarah Bigham, Michael Spiro, Margaret M. Huang, Beenish Iqbal, Sarah Trenfield, Stephane Ledot, Sujal Desai, Lewis Standing, Judith Babar, Razeen Mahroof, Ian Smith, Kai Lee, Nairi Tchrakian, Stephanie Uys, William Ricketts, Anant R.C. Patel, Avinash Aujayeb, Maria Kokosi, Alexander J.K. Wilkinson, Stefan J. Marciniak
10 September 2020
Pneumothorax and pneumomediastinum have both been noted to complicate cases of COVID-19 requiring hospital admission. The research team reported the largest case series yet described of patients with both these pathologies that includes non-ventilated patients.
Cases were collected retrospectively from UK hospitals with inclusion criteria limited to a diagnosis of COVID-19 and the presence of either pneumothorax or pneumomediastinum. Patients included in the study presented between March and June 2020. Details obtained from the medical record included demographics, radiology, laboratory investigations, clinical management and survival.
Seventy-one patients from 16 centres were included in the study, of whom 60 patients had pneumothoraces (six also with pneumomediastinum), whilst 11 patients had pneumomediastinum alone.
Survival at 28 days was not significantly different following pneumothorax or isolated pneumomediastinum. The incidence of pneumothorax was higher in males. The 28-day survival was not different between the sexes. Patients above the age of 70 had a significantly lower 28-day survival than younger individuals.
These cases suggest that pneumothorax is a complication of COVID-19. Pneumothorax does not seem to be an independent marker of poor prognosis and the researchers encourage active treatment to be continued where clinically possible.
Anthony Martinelli and Margaret Huang are supported by the Wellcome Trust. Stefan Marciniak is supported by the Medical Research Council, NIHR Cambridge BRC, Royal Papworth Hospital and the Alpha1-Foundation.
Click to read: Punctured lung affects almost one in a hundred hospitalised COVID-19 patientsView publication
15Development and validation of an LC-MS/MS method for detection and quantification of in vivo derived metabolites of [Pyr1]apelin-13 in humans
Duuamene Nyimanu, Richard G. Kay, Petra Sulentic, Rhoda E. Kuc, Philip Ambery, Lutz Jermutus, Frank Reimann, Fiona M. Gribble, Joseph Cheriyan, Janet J. Maguire, Anthony P. Davenport
27 December 2019
An LC-MS method was developed to measure Apelin in human plasma, and demonstrate apelin dosing achieved the correct concentration in volunteers. The extracts were also analysed on an LC-MS system to identify break-down products of the peptide that were produced in the body. The researchers found out that apelin is broken down from both ends of the peptide, but more so from the C-terminal. This information can be used to develop a better peptide that is stabilised against degradation, therefore improving its characteristics as a drug; and apelin-derived peptides may be potential new drugs for cardiovascular disease.View publication
16World Health Organisation cardiovascular disease risk charts: revised models to estimate risk in 21 global regions
Publication: The Lancet Global Health
Stephen Kaptoge, Lisa Pennells, Dirk De Bacquer, Marie Therese Cooney, Maryam Kavousi, Oyere Onuma, Mark Woodward, Goodarz Danaei, Gregory Roth, Shanthi Mendis, Ian Graham, Cherian Varghese, Majid Ezzati, Rod Jackson, John Danesh & Emanuele Di Angelantonio
1 September 2019
Cambridge-led researchers have updated World Health Organisation (WHO) cardiovascular disease (CVD) risk prediction charts to aid efforts to reduce the burden of CVD, one of the most common non-communicable diseases world-wide and responsible for an estimated 17.8 million deaths in 2017.
The research was funded by the National Institute for Health Research Cambridge Biomedical Research Centre, WHO, British Heart Foundation (BHF), BHF Cambridge Centre for Research Excellence and UK Medical Research Council.
The revised risk models will help particularly middle- to low-income countries in their efforts to prevent and control CVD. Full story hereView publication
17Epicardial cells derived from human embryonic stem cells augment cardiomyocyte-driven heart regeneration
Publication: Nature Biotechnology
Johannes Bargehr, Lay Ping Ong, Maria Colzani, Hongorzul Davaapil, Peter Hofsteen, Shiv Bhandari, Laure Gambardella, Nicolas Le Novère, Dharini Iyer, Fotios Sampaziotis, Florian Weinberger, Alessandro Bertero, Andrea Leonard, William G. Bernard, Amy Martinson, Nichola Figg, Michael Regnier, Martin R. Bennett, Charles E. Murry & Sanjay Sinha
2 August 2019
Transplanting an area of damaged tissue with a combination of both heart and muscle cells and supportive cells taken from the outer layer of the heart wall, may be able to help the organs recover from the damage caused by a heart attack. Part funded by the BHF and NIHR and supported by the NIHR Cambridge BRC, researchers have used supportive epicardial cells developed from human stem cells to help transplanted heart cells live longer. Full story hereView publication
Publication: Nature Medicine
Felipe A. Vieira Braga, Gozde Kar, Marijn Berg, Orestes A. Carpaij, Krzysztof Polanski, Lukas M. Simon, Sharon Brouwer, Tomás Gomes, Laura Hesse, Jian Jiang, Eirini S. Fasouli, Mirjana Efremova, Roser Vento-Tormo, Carlos Talavera-López, Marnix R. Jonker, Karen Affleck, Subarna Palit, Paulina M. Strzelecka, Helen V. Firth, Krishnaa T. Mahbubani, Ana Cvejic, Kerstin B. Meyer, Kourosh Saeb-Parsy, Marjan Luinge, Corry-Anke Brandsma, Wim Timens, Ilias Angelidis, Maximilian Strunz, Gerard H. Koppelman, Antoon J. van Oosterhout, Herbert B. Schiller, Fabian J. Theis, Maarten van den Berge, Martijn C. Nawijn, Sarah A. Teichmann
17 June 2019
This research carried out a survey of structural and immune cells in the airways of healthy and asthmatic lungs and identified a novel set of T cells resident in asmatic airways. There is altered communication between immune and structural cells in asthmatic airways and these changes underlie the inflammation in these airways.View publication
19Quantifying normal human brain metabolism using hyperpolarized [1-(13)C]pyruvate and magnetic resonance imaging
Grist JT, McLean MA, Riemer F, Schulte RF, Deen SS, Zaccagna F, et al.
1 April 2019View publication
Publication: Journal of the American College of Cardiology Volume 73, Issue 10, 19 March 2019, Pages 1107-1119
Cartlidge TRG, Doris MK, Sellers SL, Pawade TA, White AC, Pessotto R, Kwiecinski J, Fletcher A, Alcaide C, Lucatelli .
19 March 2019View publication
21An unbiased lipid phenotyping approach to study the genetic determinants of lipids and their association with coronary heart disease risk factors.
Publication: J Proteome Res
Harshfield EL, Koulman A, Ziemek D, Marney L, Fauman EB, Paul DS, et al.
19 March 2019View publication
22Stiffening and ventricular-arterial interaction in the ascending aorta using MRI: ageing effects in healthy humans
Publication: Journal of Hypertension
Li Y, Hickson SS, McEniery CM, Wilkinson IB, Khir AW.
February 2019View publication
23New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries.
Publication: Nature Genetics
Shrine N, Guyatt AL, Erzurumluoglu AM, Jackson VE, Hobbs BD, Melbourne CA, et al.
25 February 2019View publication
24Methods and considerations concerning cardiac output measurement in pregnant women: recommendations of the International Working Group on Maternal Hemodynamics.
Publication: Ultrasound Obstetrics Gynecology
Bijl RC, Valensise H, Novelli GP, Vasapollo B, Wilkinson I, Thilaganathan B, et al.
8 February 2019View publication
Publication: European Respiratory Journal
Nathan SD, Barbera JA, Gaine SP, Harari, S, Martinez FJ, Olschewski H, Olsson KM, Peacock AJ, Pepke-Zaba J, Provencher S, Weissmann N, Werner Seeger W.
13 December 2018View publication
26A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program—AIM-HY INFORM trial
Publication: American Heart Journal
Mukhtar O, Cheriyan J, Cockcroft JR, Collier D, Coulson JM, Dasgupta I, et al.
October 2018View publication
27Interventions to increase referral and uptake to pulmonary rehabilitation in people with COPD: a systematic review
Publication: International Journal of Chronic Obstructive Pulmonary Disease
Early F, Wellwood I, Kuhn I, Deaton C, Fuld J.Int
29 October 2018View publication
Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al.
6 June 2018View publication
29A Randomised Controlled Trial of High versus Ad Libitum Water Intake in Patients with Autosomal Dominant Polycystic Kidney Disease: Rationale and Design of the DRINK Feasibility Trial
R El-Damanawi, M Lee, T Harris, L Mader, S Bond, H Pavey, et al.
9 May 2018View publication
30Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies
Publication: The Lancet
Angela M Wood PhD, P, Stephen Kaptoge, PhD, Adam S Butterworth, PhD, Peter Willeit, MD, Samantha Warnakula, PhD, Thomas Bolton, MMath, Ellie Paige, PhD, Dirk S Paul, PhD, Michael Sweeting, PhD, Stephen Burgess, PhD, Steven Bell, PhD, William Astle, PhD, David Stevens, MSc, Albert Koulman, PhD, Randi M Selmer, PhD, Prof W M Monique Verschuren, PhD, Prof Shinichi Sato, MD, Prof Inger Njølstad, MD, Prof Mark Woodward, PhD, Prof Veikko Salomaa, MD, Prof Børge G Nordestgaard, MD, Prof Bu B Yeap, MBBS, Prof Astrid Fletcher, PhD, Prof Olle Melander, MD, Prof Lewis H Kuller, MD, Beverley Balkau, PhD, Prof Michael Marmot, FMedSci, Prof Wolfgang Koenig, MD, Prof Edoardo Casiglia, MD, Prof Cyrus Cooper, FMedSci, Volker Arndt, MD, Prof Oscar H Franco, MD, Patrik Wennberg, MD, Prof John Gallacher, PhD, Agustín Gómez de la Cámara, MD, Prof Henry Völzke, MD, Christina C Dahm, PhD, Caroline E Dale, PhD, Manuela M Bergmann, PhD, Carlos J Crespo, PhD, Prof Yvonne T van der Schouw, PhD, Prof Rudolf Kaaks, MD, Leon A Simons, MD, Pagona Lagiou, MD, Josje D Schoufour, PhD, Jolanda M A Boer, PhD, Prof Timothy J Key, DPhil, Beatriz Rodriguez, MD, Conchi Moreno-Iribas, PhD, Karina W Davidson, PhD, James O Taylor, MD, Carlotta Sacerdote, PhD, Prof Robert B Wallace, MD, J Ramon Quiros, MD, Prof Rosario Tumino, MD, Dan G Blazer II, MD, Prof Allan Linneberg, MD, Makoto Daimon, MD, Salvatore Panico, MD, Barbara Howard, PhD, Guri Skeie, PhD, Prof Timo Strandberg, MD, Prof Elisabete Weiderpass, PhD, Prof Paul J Nietert, PhD, Prof Bruce M Psaty, MD, Prof Daan Kromhout, PhD, Elena Salamanca-Fernandez, MSc, Prof Stefan Kiechl, MD, Prof Harlan M Krumholz, MD, Sara Grioni, BSc, Domenico Palli, MD, José M Huerta, PhD, Prof Jackie Price, MD, Prof Johan Sundström, MD, Larraitz Arriola, MD, Prof Hisatomi Arima, MD, Ruth C Travis, DPhil, Prof Demosthenes B Panagiotakos, PhD, Anna Karakatsani, MD, Prof Antonia Trichopoulou, MD, Tilman Kühn, PhD, Prof Diederick E Grobbee, MD, Elizabeth Barrett-Connor, MD, Natasja van Schoor, MD, Prof Heiner Boeing, PhD, Prof Kim Overvad, MD, Prof Jussi Kauhanen, MD, Prof Nick Wareham, MD, Claudia Langenberg, MD, Prof Nita Forouhi, PhD, Maria Wennberg, PhD, Prof Jean-Pierre Després, DPhil, Prof Mary Cushman, MD, Jackie A Cooper, MSc, Prof Carlos J Rodriguez, MD, Masaru Sakurai, MD, Jonathan E Shaw, PhD, Prof Matthew Knuiman, PhD, Trudy Voortman, PhD, Prof Christa Meisinger, MD, Anne Tjønneland, MD, Prof Hermann Brenner, MD, Luigi Palmieri, PhD, Jean Dallongeville, MD, Prof Eric J Brunner, PhD, Prof Gerd Assmann, MD, Maurizio Trevisan, MD, Richard F Gillum, MD, Prof Ian Ford, PhD, Prof Naveed Sattar, FMedSci, Mariana Lazo, MD, Prof Simon G Thompson, FMedSci, Pietro Ferrari, PhD, Prof David A Leon, PhD, Prof George Davey Smith, MD, Prof Richard Peto, FRS, Prof Rod Jackson, PhD, Prof Emily Banks, PhD, Emanuele Di Angelantonio, MD, Prof John Danesh
14 April 2018
Regularly drinking more than the recommended UK guidelines for alcohol could take years off your life, according to new research from the University of Cambridge. The study shows that drinking more alcohol is associated with a higher risk of stroke, fatal aneurysm, heart failure and death.
The authors say their findings challenge the widely held belief that moderate drinking is beneficial to cardiovascular health, and support the UK’s recently lowered guidelines. The study compared the health and drinking habits of over 600,000 people in 19 countries worldwide and controlled for age, smoking, history of diabetes, level of education and occupation.
Publication: Nature Communications
Stefan Gräf, Matthias Haimel, Marta Bleda, Charaka Hadinnapola, Laura Southgate, Wei Li, Joshua Hodgson, Bin Liu, Richard M. Salmon, Mark Southwood, Rajiv D. Machado, Jennifer M. Martin, Carmen M. Treacy, Katherine Yates, Louise C. Daugherty, Olga Shamardina, Deborah Whitehorn, Simon Holden, Micheala Aldred, Harm J. Bogaard, Colin Church, Gerry Coghlan, Robin Condliffe, Paul A. Corris, Cesare Danesino, Mélanie Eyries, Henning Gall, Stefano Ghio, Hossein-Ardeschir Ghofrani, J. Simon R. Gibbs, Barbara Girerd, Arjan C. Houweling, Luke Howard, Marc Humbert, David G. Kiely, Gabor Kovacs, Robert V. MacKenzie Ross, Shahin Moledina, David Montani, Michael Newnham, Andrea Olschewski, Horst Olschewski, Andrew J. Peacock, Joanna Pepke-Zaba, Inga Prokopenko, Christopher J. Rhodes, Laura Scelsi, Werner Seeger, Florent Soubrier, Dan F. Stein, Jay Suntharalingam, Emilia M. Swietlik, Mark R. Toshner, David A. van Heel, Anton Vonk Noordegraaf, Quinten Waisfisz, John Wharton, Stephen J. Wort, Willem H. Ouwehand, Nicole Soranzo, Allan Lawrie, Paul D. Upton, Martin R. Wilkins, Richard C. Trembath & Nicholas W. Morrell
12 April 2018
Pulmonary Arterial Hypertension (PAH) is a fatal lung disease and causes the walls of the arteries become thick and stiff, narrowing the space for blood to pass through and increasing blood pressure then leading to heart failure.
The disease kills 50% of those affected within five years, but little was known about what caused the condition in some people. Now experts say they have discovered five genes that cause the illness and could pave the way for more treatments.
Scientists carried out the largest ever genetic study of the disease by analysing the genomes – the unique sequence of a person’s DNA – of more than 1,000 PAH patients for whom the cause of the illness was unknown.
They found that mutations in five genes were responsible for causing the illness in these people, including in four genes that were not previously known to be involved in the disease. In people with the condition these genes fail to effectively produce the proteins that are required for the structure, function and regulation of the body’s tissues, researchers found.View publication
Publication: Nature Reviews Neurology
Evans NR, Tarkin JM, Buscombe JR, Markus HS, Rudd JHF, Warburton EA.
3 April 2018View publication
33TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling
Publication: Nature Communications
Hurst LA, Dunmore BJ, Long L, Crosby A, Al-Lamki R, Deighton J, Southwood M, Yang X, Nikolic MZ, Herrera B, Inman GJ, Bradley JR, Rana AA, Upton PD, Morrell NW
13 January 2017View publication
34High Structural Stress and Presence of Intraluminal Thrombus Predict Abdominal Aortic Aneurysm 18F-FDG Uptake: Insights From Biomechanics
Publication: Circ Cardiovasc Imaging
Huang Y, Teng Z, Elkhawad M, Tarkin JM, Joshi N, Boyle JR, Buscombe JR, Fryer TD, Zhang Y, Park AY, Wilkinson IB, Newby DE, Gillard JH, Rudd JH.
November 2016View publication
35Acute Respiratory Distress Syndrome Neutrophils Have a Distinct Phenotype and Are Resistant to Phosphoinositide 3-Kinase Inhibition.
Publication: Am J Respir Crit Care Med
Juss JK, House D, Amour A, Begg M, Herre J, Storisteanu DM, Hoenderdos K, Bradley G, Lennon M, Summers C, Hessel EM, Condliffe A, Chilvers ER.
15 October 2016View publication
Publication: Proc Natl Acad Sci U S A
Cowburn AS, Crosby A, Macias D, Branco C, Colaço RD, Southwood M, Toshner M, Crotty Alexander LE, Morrell NW, Chilvers ER, Johnson RS.
18 July 2016View publication
37Plaque Structural Stress Estimations Improve Prediction of Future Major Adverse Cardiovascular Events After Intracoronary Imaging
Publication: Circ Cardiovasc Imaging
Brown AJ, Teng Z, Calvert PA, Rajani NK, Hennessy O, Nerlekar N, Obaid DR, Costopoulos C, Huang Y, Hoole SP, Goddard M, West NE, Gillard JH, Bennett MR.
June 2016View publication
38BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis
Publication: Lancet Respir Med
Evans JD, Girerd B, Montani D, Wang XJ, Galiè N, Austin ED, Elliott G, Asano K, Grünig E, Yan Y, Jing ZC, Manes A, Palazzini M, Wheeler LA, Nakayama I, Satoh T, Eichstaedt C, Hinderhofer K, Wolf M, Rosenzweig EB, Chung WK, Soubrier F, Simonneau G, Sitbon O, Gräf S, Kaptoge S, Di Angelantonio E, Humbert M, Morrell NW.
19 January 2016View publication
39Direct Comparison of Virtual-Histology Intravascular Ultrasound and Optical Coherence Tomography Imaging for Identification of Thin-Cap Fibroatheroma
Publication: Circ Cardiovasc Imaging
Brown AJ, Obaid DR, Costopoulos C, Parker RA, Calvert PA, Teng Z, Hoole SP, West NE, Goddard M, Bennett MR.
8 October 2015View publication
40Identifying active vascular microcalcification by (18)F-sodium fluoride positron emission tomography
Publication: Nat Commun
Irkle A, Vesey AT, Lewis DY, Skepper JN, Bird JL, Dweck MR, Joshi FR, Gallagher FA, Warburton EA, Bennett MR, Brindle KM, Newby DE, Rudd JH, Davenport AP.
7 July 2015View publication
41Clinical application of autologous technetium-99m-labelled eosinophils to detect focal eosinophilic inflammation in the lung
Loutsios C, Farahi N, Simmonds R, Cullum I, Gillett D, Solanki C, Solanki K, Buscombe J, Condliffe AM, Peters AM, Chilvers ER.
24 June 2015View publication
Publication: Nat Med.
Long L, Ormiston ML, Yang X, Southwood M, Gräf S, Machado RD, Mueller M, Kinzel B, Yung LM, Wilkinson JM, Moore SD, Drake KM, Aldred MA, Yu PB, Upton PD, Morrell NW.
15 June 2015View publication